References
- Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111:3778–3792.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–246.
- Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99:1556–1563.
- Inoue D, Maruyama K, Aoki K, et al. Blastic plasmacytoid dendritic cell neoplasm expressing the CD13 myeloid antigen. Acta Haematol. 2011;126:122–128.
- Matsuo T, Ichimura K, Tanaka T, et al. Bilateral conjunctival lesions in blastic plasmacytoid dendritic cell neoplasm. J Clin Exp Hematop. 2011;51:49–55.
- Vigemyr G. [An young boy with an atypic rash]. Tidsskr nor Laegeforen. 2014;134:946–948.
- Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169:579–586.
- Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174–10181.